Korea's Celltrion Cuts Deal With Jordan-Based Hikma To Sell Its Biosimilars In The Middle East, Africa
This article was originally published in The Pink Sheet Daily
Celltrion has been developing nine blockbuster biosimilar therapeutic antibodies in line with a bid to launch three in markets not protected with patent rights. The firm is moving to globally launch the biosimilars around 2011.
You may also be interested in...
SEOUL - As part of its bid to stretch out for more global sales for a range of antibody therapeutic biosimilars, Celltrion has signed a deal with Perrigo to market its products in Israel
Korea's Celltrion Gains Foothold in Europe; Wins Clinical Trial Approval from Latvia For Herceptin Biosimilar
SEOUL - South Korea's Celltrion has secured an approval from EU member Latvia to perform clinical trials for its Herceptin (trastuzumab) biosimilar as part of its effort to prepare for the expiration of Roche's patent rights on the product in 2019 in Europe and the U.S
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News